Exactech Innovations Presented at Key Scientific Conference
October 26 2015 - 11:36AM
Business Wire
New Studies Support Company’s Knee, Shoulder
and ExactechGPS® Technologies
Exactech, Inc. (Nasdaq:EXAC), a developer and producer of bone
and joint restoration products for hip, knee, shoulder and spine,
today recounted 18 studies presented at key scientific conferences
this Fall, including an Equinoxe® shoulder study which won
the “1st Place E-Poster Award” at the 28th Congress of The
International Society of Technology in Arthroplasty (ISTA).
The award-winning poster, Rate of Improvement in Clinical
Outcomes with Anatomic and Reverse Total Shoulder Arthroplasty,
featured the clinical outcomes of 1,641 patients and compared the
rate of clinical improvement of patients with anatomic total
shoulder arthroplasty with those of patients with reverse total
shoulder arthroplasty.
“This study is significant because it quantifies how patient
outcomes improve with time following treatment with both anatomic
and reverse total shoulder arthroplasty,” said Ryan Simovitch,
M.D., Palm Beach, Fla., one of the authors. “These results can be
used to establish realistic patient expectations regarding the
typical follow-up time required for pain to be reduced and function
restored following surgical treatment with a total shoulder
prosthesis.”
Presentations featuring Exactech Knee and
ExactechGPS® Guided Personalized Surgery
A cadaveric study led by Michael Cross, MD, assistant attending
orthopaedic surgeon at Hospital for Special Surgery, New York,
evaluated Exactech’s patented CR Slope® knee implant system
and posterior cruciate retaining technique using
ExactechGPS® guided personalized surgery. The results
demonstrated that a change in the posterior tibial slope can
significantly impact knee kinematics in patients.
“Exactech’s CR Slope® design provides surgeons with
intra-operative flexibility to adjust the posterior slope of the
tibia without having to perform additional re-cuts,” said Dr.
Cross. “The study proved that with this approach, the surgeon can
optimize knee kinematics and flexion gap tension easily and quickly
without altering the bony cuts.”
Another study reported on the ExactechGPS and its tracker
visibility. In this study, the rotational line-of-sight limit for
the ExactechGPS trackers and camera was quantified. The results
demonstrated that ExactechGPS provides tracker visibility for more
than 135 degrees of rotation across the surgical field, providing
excellent tracking intra-operatively with minimum line-of-sight
restrictions.
“This study showcased ExactechGPS and its important advantages
over other navigation systems,” said Barton Harris, MD,
Mechanicsville, VA. “The data showed that ExactechGPS has a wider
field of view and trackers that accommodate significant rotation
relative to the unit. It also has a compact combined camera and
digital screen interface, placed within the sterile field, which
allows orthopaedic surgeons to be able to work with the technology
rather than around it.”
The Exactech Knee studies included:
- Effect of Cement Layer on Tibial
Component Alignment and Joint Height During Total Knee
Arthroplasty
- The Effect of Posterior Tibial Slope on
the Kinematics of PCL-Retaining TKA
- Evaluation of Tracker Visibility during
Computer-Assisted Total Knee Arthroplasty
- Evaluation of Native Knee Kinematics
and the Effect of Arthrotomy
- How Should We Select the Worse Case for
TKA Implant Testing?
- Novel Test Method to Evaluate the
Effect of Posterior Tibial Slope on the Kinematics of PCL-Retaining
Total Knee Arthroplasty
- Size Relationship Between Femoral and
Patellar Implants in TKA Patients
- Effect of Leg Position on the
Intraoperative Measurement of Planned Resection during
Computer-Assisted Total Knee Arthroplasty
- ExactechGPS Guidance System Does Not
Increase Operative Time When Compared to Conventionally
Instrumented Total Knee Arthroplasty
- Accuracy Comparison Between Two
Contemporary Caos Systems
- Intraoperative Evaluation of Achieved
Bony Resections During TKA: Is It Caos System-Dependent?
Presentations Featuring Exactech’s Equinoxe®
Shoulder System
In addition to the award-winning presentation, a large scale
clinical study objectively addressed a controversial topic in the
literature regarding the negative impact of scapular notching on
clinical outcomes in patients with reverse shoulder arthroplasty.
The outcomes of 415 patients at 38.3 months average follow-up
demonstrated a scapular notching rate of 12.5 percent, which was
very favorable relative to the reported rates in the literature
(six times lower than competitive systems).
The Exactech Shoulder studies included:
- The Effect of Axillary Crutch Use
Following rTSA on Reverse Shoulder Baseplate Fixation
- Impact of Anterior Glenoid Defects on
Reverse Shoulder Glenoid Fixation
- Comparison of Clinical Outcomes with
Reverse Total Shoulder Arthroplasty in Patients with and without
Scapular Notching
- Clinical Outcome Comparison of
Augmented Glenoid Components vs Glenoid Bone Grafting with Reverse
Total Shoulder Arthroplasty
- Rate of Improvement in Clinical
Outcomes with Anatomic and Reverse Total Shoulder Arthroplasty
- Comparison of Clinical Outcomes with
Posteriorly Augmented Glenoid Components with Anatomic and Reverse
Total Shoulder Arthroplasty
- The Effect of Shooting Firearms on
Reverse Shoulder Baseplate Fixation
About ISTA
The International Society of Technology in Arthroplasty (ISTA)
is a non-profit organization dedicated to advancing the art and
science of joint replacement around the world. Every year it hosts
a congress where the best clinicians, engineers, researchers, and
industry members from across the globe come together to present and
discuss leading edge work in the field of arthroplasty.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech, Inc. can be found at
http://www.exac.com. Copies of Exactech’s press releases, SEC
filings, current price quotes and other valuable information for
investors may be found at http://www.exac.com and
http://www.hawkassociates.com.
An investment profile on Exactech may be found at
http://www.hawkassociates.com/profile/exac.cfm. To receive future
releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151026006087/en/
Exactech, Inc.Investor Contacts:Jody Phillips,
352-377-1140Executive Vice President of Finance &Chief
Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins,
305-451-1888EXAC@hawkassociates.comorMedia Contact:Priscilla
Bennett, 352-377-1140Vice President, Corporate & Marketing
Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2023 to Apr 2024